Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA

BACKGROUND: HER2-amplified breast cancer is a clinically defined subtype of breast cancer for which there are multiple viable targeted therapies. Resistance to these targeted therapies is a common problem, but the mechanisms by which resistance occurs remain incompletely defined. One mechanism that...

Descripción completa

Detalles Bibliográficos
Autores principales: Garay, Joseph P., Smith, Rebecca, Devlin, Kaylyn, Hollern, Daniel P., Liby, Tiera, Liu, Moqing, Boddapati, Shanta, Watson, Spencer S., Esch, Amanda, Zheng, Ting, Thompson, Wallace, Babcock, Darcie, Kwon, Sunjong, Chin, Koei, Heiser, Laura, Gray, Joe W., Korkola, James E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336338/
https://www.ncbi.nlm.nih.gov/pubmed/34344439
http://dx.doi.org/10.1186/s13058-021-01457-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336338/
https://www.ncbi.nlm.nih.gov/pubmed/34344439
http://dx.doi.org/10.1186/s13058-021-01457-0

Ejemplares similares